<?xml version="1.0" encoding="utf-8"?>
<journal>
<title>International Journal of Radiation Research</title>
<title_fa>نشریه پرتو پژوه</title_fa>
<short_title>Int J Radiat Res</short_title>
<subject>Basic Sciences</subject>
<web_url>http://ijrr.com</web_url>
<journal_hbi_system_id>79</journal_hbi_system_id>
<journal_hbi_system_user>journal79</journal_hbi_system_user>
<journal_id_issn>2322-3243</journal_id_issn>
<journal_id_issn_online>2345-4229</journal_id_issn_online>
<journal_id_pii></journal_id_pii>
<journal_id_doi>10.61882/ijrr</journal_id_doi>
<journal_id_iranmedex></journal_id_iranmedex>
<journal_id_magiran></journal_id_magiran>
<journal_id_sid></journal_id_sid>
<journal_id_nlai></journal_id_nlai>
<journal_id_science></journal_id_science>
<language>en</language>
<pubdate>
	<type>jalali</type>
	<year>1401</year>
	<month>4</month>
	<day>1</day>
</pubdate>
<pubdate>
	<type>gregorian</type>
	<year>2022</year>
	<month>7</month>
	<day>1</day>
</pubdate>
<volume>20</volume>
<number>3</number>
<publish_type>online</publish_type>
<publish_edition>1</publish_edition>
<article_type>fulltext</article_type>
<articleset>
	<article>


	<language>en</language>
	<article_id_doi></article_id_doi>
	<title_fa></title_fa>
	<title>Clinical implementation of a PRIMO Monte Carlo-based dose verification and quality assurance model for stereotactic body radiotherapy (SBRT) treatment plans of the lung</title>
	<subject_fa>Radiation Biology</subject_fa>
	<subject>Radiation Biology</subject>
	<content_type_fa>تحقيق بديع</content_type_fa>
	<content_type>Original Research</content_type>
	<abstract_fa></abstract_fa>
	<abstract>&lt;div style=&quot;text-align: justify;&quot;&gt;&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;text-justify:inter-word&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Background&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Natural &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;The validation and clinical implementation of the PRIMO Monte Carlo (MC) model of Clinac&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:5.9939pt&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;&lt;sup&gt;&amp;reg;&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;iX Linear accelerator as an independent dose verification and quality assurance (QA) tool for the SBRT lung treatment plans. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Materials and Methods&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt; An independent MC based dose verification was performed for ten volumetric modulated arc therapy (VMAT) SBRT treatment plans.The plans generated in the Varian Eclipse treatment planning system (TPS) were recalculated with a PRIMO MC system for identical beam parameters.The log file-based QA was performed by comparing the TPS dose against the dose reconstructed from machine log files and the results were cross-verified with the Mobius3D&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:5.9939pt&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;&lt;sup&gt;&amp;reg;&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt; verification system. The dose-volume histogram (DVH) based plan comparison and 3D global gamma analysis were carried out. The statistical significance of the differences was tested with the Wilcoxon signed-rank test with a significance level of P &lt; 0.05. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Results&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;No statistically significant differences were observed in PTV and organs at risk (OARs) DVH parameters except for the PTVmax dose for both TPS vs PRIMO independent dose check and TPS vs PRIMO dynalog based QA. The 3D gamma analysis results show a minimum pass rate of 95% between TPS and PRIMO. Mobius3D&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:5.9939pt&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;&lt;sup&gt;&amp;reg;&lt;/sup&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt; results showed a slightly higher percentage variation in the mean dose to PTV and OARs and a slightly lower gamma pass than TPS vs PRIMO results. &lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;Conclusion&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:#1f497d&quot;&gt;&lt;span style=&quot;font-weight:bold&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;:&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;This study showed that a validated MC model of PRIMO could be used as an effective tool for independent dose verification and machine log-files-based quality assurance of VMAT SBRT plans.&lt;/span&gt;&lt;/span&gt;&lt;/span&gt; &amp;nbsp;&lt;span lang=&quot;en-US&quot; style=&quot;font-size:9.0pt&quot;&gt;&lt;span style=&quot;font-family:Tahoma&quot;&gt;&lt;span style=&quot;font-style:italic&quot;&gt;&lt;span style=&quot;language:en-US&quot;&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/div&gt;
&lt;span style=&quot;font-size:10pt&quot;&gt;&lt;span style=&quot;line-height:119%&quot;&gt;&lt;span style=&quot;font-family:Calibri&quot;&gt;&lt;span style=&quot;color:black&quot;&gt;&amp;nbsp;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;/span&gt;&lt;br&gt;
&amp;nbsp;</abstract>
	<keyword_fa></keyword_fa>
	<keyword>Monte Carlo, independent secondary dose check, PRIMO, dynalog.</keyword>
	<start_page>563</start_page>
	<end_page>570</end_page>
	<web_url>http://ijrr.com/browse.php?a_code=A-10-1-946&amp;slc_lang=en&amp;sid=1</web_url>


<author_list>
	<author>
	<first_name>B. </first_name>
	<middle_name></middle_name>
	<last_name>Sarin</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email>sreesarin@gmail.com </email>
	<code>7900319475328460021917</code>
	<orcid>7900319475328460021917</orcid>
	<coreauthor>Yes
</coreauthor>
	<affiliation>Department of Physics, Noorul Islam Centre for Higher Education, Kumaracoil, Kanyakumari, Tamil Nadu, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>B. </first_name>
	<middle_name></middle_name>
	<last_name>Bindhu</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460021918</code>
	<orcid>7900319475328460021918</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Department of Physics, Noorul Islam Centre for Higher Education, Kumaracoil, Kanyakumari, Tamil Nadu, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>B. </first_name>
	<middle_name></middle_name>
	<last_name>Saju</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460021919</code>
	<orcid>7900319475328460021919</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>P. </first_name>
	<middle_name></middle_name>
	<last_name>Raghukumar</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460021920</code>
	<orcid>7900319475328460021920</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


	<author>
	<first_name>R.K. </first_name>
	<middle_name></middle_name>
	<last_name>Nair</last_name>
	<suffix></suffix>
	<first_name_fa></first_name_fa>
	<middle_name_fa></middle_name_fa>
	<last_name_fa></last_name_fa>
	<suffix_fa></suffix_fa>
	<email></email>
	<code>7900319475328460021921</code>
	<orcid>7900319475328460021921</orcid>
	<coreauthor>No</coreauthor>
	<affiliation>Division of Radiation Physics, Regional Cancer Centre, Thiruvananthapuram, Kerala, India</affiliation>
	<affiliation_fa></affiliation_fa>
	 </author>


</author_list>


	</article>
</articleset>
</journal>
